This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Revascularization  • Cardiovascular Interventions, Other  • Cardiovascular System  • Surgery  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Drug Therapy  • Adverse Effects  • Cardiovascular Intervention  • Alert me on articles by topic  Social Bookmarking   What's this?

Hope, Hype, Humility, and Advancing Patient Care

Robert A. Harrington, MD; E. Magnus Ohman, MD

JAMA. 2007;297(18):2028-2030.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Interventional cardiology is an iterative science. Advances come in spurts as interventionalists gradually become increasingly familiar with its technologies and limitations. This iterative learning process in the use of percutaneous coronary intervention (PCI) has been tremendous over the last 3 decades. While adverse events were frequent and restenosis was common in the first decade, PCI procedures did relieve symptoms for patients with coronary disease. In the second decade of PCI use, new techniques were developed to scrape, burn, or excise plaque, in an attempt to achieve better outcomes. While there was much hope and hype with these approaches, they all had fundamental problems that prevented their broader use.

Intracoronary bare-metal stents humbled clinicians because warfarin was initially required to prevent in-stent thrombosis and resulted in bleeding complications in many patients. Advances in delivery of bare-metal stents, application of high-pressure balloon inflation, and . . . [Full Text of this Article]

Author Affiliations: Division of Cardiology, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Outside the operating room--economic, regulatory, and legal challenges: A collection of perspectives and panel discussion
ALTMAN et al.
Cleveland Clinic Journal of Medicine 2008;75:S61-S73.
FULL TEXT  

What Do You Need to Know Before Performing a Percutaneous Coronary Intervention?
Cavender and Ohman
Circulation 2008;118:609-611.
FULL TEXT  

Outcomes Following Coronary Stenting in the Era of Bare-Metal vs the Era of Drug-Eluting Stents
Malenka et al.
JAMA 2008;299:2868-2876.
ABSTRACT | FULL TEXT  

Comparison of Paclitaxel- and Sirolimus-Eluting Stents in Everyday Clinical Practice: The SORT OUT II Randomized Trial
Galloe et al.
JAMA 2008;299:409-416.
ABSTRACT | FULL TEXT  

Defining and utilizing surrogates in the evaluation of coronary stents: what do we really want and need to know?
Harrington et al.
J Am Coll Cardiol 2008;51:33-36.
FULL TEXT  

Off-Label Drug-Eluting Stent Use Increases Risk for Adverse Events
Journal Watch Cardiology 2007;2007:1-1.
FULL TEXT  

Off-Label Use of Drug-Eluting Coronary Artery Stents
JWatch General 2007;2007:3-3.
FULL TEXT